SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

Mar 25 2014

Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. (SIFI) and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.

The products include prescription drugs to treat patients undergoing ocular interventions or suffering from infections or inflammatory diseases of the eye.

In particular, the portfolio includes two artificial tear formulations, Eyestil^TM and Lacrisifi^TM, developed to treat dry eye conditions resulting from altered or reduced tear production. Additionally, Colbiocin^TM, Nettavisc^TM and Nettacin^TM offer three antibiotic options, available in multiple dosage forms, for the treatment of external eye infections. Prenacid^TM is a water-soluble corticosteroid indicated for treatment of inflammations, including post-surgical inflammations, and allergies. Octilia^TM is an eye drop solution indicated for treatment of irritations, reddening, ocular congestion and pruritus due to allergic, chemical or physical causes. Lastly, Mirtilene Forte^TM is a retinotrophic with a vasoprotective action helpful in cases of capillary fragility or vascular alterations due to diabetic retinopathy.

All the drugs have undergone clinical studies and are registered in Russia and the European Union. NovaMedica plans to initiate sales of some of these products in Russia later this year.

"Combined with other advanced pharmaceuticals already in NovaMedica's pipeline, the SIFI products contribute to the creation of a balanced NovaMedica portfolio with drugs and therapies in place to meet the needs of both ophthalmologists and patients across a wide variety of ocular conditions," said Fabrice Egros, NovaMedica COO. "This partnership enables us to quickly bring the latest therapies in the ophthalmology sector to Russian patients, a key element serving our short- and long-term strategy."

"We are pleased to strengthen our international distribution network through the agreement with NovaMedica," stated Stefano Salvati, SIFI CEO. "Our cooperation leads to a wide-open and effective access to the rapidly growing ophthalmology market in Russia and other CIS countries. This agreement also offers an opportunity for further joint business activities and, undoubtedly, it will contribute to a broader availability of advanced ocular therapies to Russian patients."